Categories: News

Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022

MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the fourth quarter and full year of 2021 after the market close on Monday, March 14th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 562-0146 for domestic callers or (661) 567-1226 for international callers, followed by Conference ID: 5291099. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

Akoya also announced that it will be virtually participating in the Cowen Annual Health Care Conference. Brian McKelligon, CEO, and Joe Driscoll, CFO, are scheduled to present on Tuesday, March 8th, 2022 at 9:50 a.m. ET. A live and archived webcast of the event will be available on the “Investors” section of the Akoya website at https://investors.akoyabio.com/.

About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research via its key platforms: PhenoCycler™, PhenoImager™ Fusion and PhenoImager HT. To learn more about Akoya, visit www.akoyabio.com.

Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
Akoya Biosciences, Inc.
investors@akoyabio.com

Media Contact:
Michelle Linn
Bioscribe, Inc.
774-696-3803
michelle@bioscribe.com

Staff

Recent Posts

Pulse Urgent Care Notifies Individuals of Data Security Incident

REDDING, Calif., Dec. 29, 2025 /PRNewswire/ -- Docs Medical Group, Inc. dba Pulse Urgent Care…

12 minutes ago

Interactive Strength Inc. (NASDAQ:TRNR) Provides Update on Sportstech Transaction

AUSTIN, TEXAS / ACCESS Newswire / December 29, 2025 / Interactive Strength Inc. (Nasdaq:TRNR) ("TRNR"…

12 minutes ago

In Spite of Trump’s Marijuana Executive Order, FDA Hemp and Marijuana Botanical Guidance Will Prevail

FDA Law-Not Hemp, Marijuana Politics-Will Decide the Future of Cannabinoid Medicine.Why "Full-Spectrum CBD" Narratives Are…

12 minutes ago

10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference

PLEASANTON, Calif., Dec. 29, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell…

6 hours ago

Tri-City Cardiology’s Ambulatory Surgical Center Surpasses 6,000 Procedures, Marking a Major Milestone in Outpatient Cardiovascular Care

MESA, Ariz., Dec. 29, 2025 /PRNewswire/ -- Tri-City Cardiology's Ambulatory Surgical Center (ASC), legally referred to…

6 hours ago

LG NOVA UNVEILS NEXT GENERATION OF AI-FIRST VENTURES AT CES 2026

Collaborative AI-First Ventures Delivers Impactful Solutions for Health, Energy, Small Business and Enterprise SectorsLAS VEGAS,…

6 hours ago